Clinical trials: Cardiovascular Disease Acute
Aneurysm, Dissection
PANTHER Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches
The purpose of this registry is to collect safety and performance data on all commercially available Terumo Aortic knitted and woven grafts, and cardiovascular patches in standard clinical practice.
- Conditions
- Aneurysm, Dissection, Aortic Root Aneurysm, Aortic Root Dissection
- Trial name
- PANTHER (NCT04545502)
- Testing
- Gelsoft Plus Vascular Graft, Vascular Bypass Graft, Cardiovascular Patch
- Where
- 30 sites in United States, Belgium and 4 more
- Volunteers
- 2,000 people
- Sponsor
- Vascutek Ltd.
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Austria Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT01667016
- Where
- 8 sites in Austria
- Volunteers
- 305 people
- Sponsor
- Biotronik Vertriebs-GmbH
Acute Coronary Syndrome, Myocardial Infarction
A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome
This prospective, non-interventional, single arm, longitudinal cohort multicenter study will recruit approximately 5600 consecutive all-comers, consisting of patients with signs and symptoms of acute coronary syndromes (ACS) who…
- Trial name
- PERFORM-TSIX (NCT06734117)
- Testing
- Elecsys® Troponin T hs Gen 6, Blood sample collection
- Where
- 50 sites in United States, Austria and 9 more
- Volunteers
- 5,429 people
- Sponsor
- Hoffmann-La Roche
Hereditary Angioedema
Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema
It is a placebo-controlled randomized trial to evaluate the efficacy and safety of GNR-038 in comparison with Berinert® in patients with hereditary angioedema
- Trial name
- NCT04898309
- Testing
- GNR-038, 50 МЕ/ kg, GNR-038, 100 МЕ/ kg, Berinert®, 20 МЕ/ kg
- Where
- 5 sites in Russia
- Sponsor
- AO GENERIUM
Acute Coronary Disease, Angina Unstable
Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS
The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a…
- Trial name
- CURRENT/OASIS7 (NCT00335452)
- Testing
- Clopidogrel, acetylsalicyclic acid (ASA)
- Where
- 38 sites in United States, Argentina and 36 more
- Volunteers
- 25,086 people
- Sponsor
- Sanofi
Acute Ischemic Stroke
Evaluation of iNstroke Aspiration Catheters for Thrombectomy: a Multi-center Prospective Study
Prospective, single-arm, multi-center study to confirm the performance and safety of the iNstroke 6F and 4F thromboaspiration catheter for the treatment of acute ischemic stroke
- Trial name
- iNDUO (NCT07376447)
- Testing
- Thromboaspiration catheter
- Where
- 11 sites in France, Germany
- Volunteers
- 160 people
- Sponsor
- iVascular S.L.U.
Acute Ischemic Stroke
Dose Finding Study of MCI-186 in Acute Ischemic Stroke
To investigate the efficacy and safety of MCI-186 (bolus followed by continuous infusion) in acute ischemic stroke patients through a double-blind, parallel-group comparison with the existing MCI-186 dosing regimen…
- Trial name
- NCT03346538
- Testing
- Continuous infusion high-dose MCI-186, Continuous infusion low-dose MCI-186, Approved dosing regimen MCI-186
- Where
- 45 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Shionogi
Injuries, Acute Brain, Severe Trauma Brain Injury (sTBI)
Bioavailability of Medium Chain Triglycerides (MCTs) in Comatose Patients With Acute Brain Injury (ABI)
This study will be targeting patients suffering from acute brain injury (ABI), including those with severe trauma brain injury (sTBI) and those with aneurysmal sub arachnoid hemorrhage (aSAH).
- Conditions
- Injuries, Acute Brain, Severe Trauma Brain Injury (sTBI), Subarachnoid Hemorrhage, Aneurysmal
- Trial name
- MCTs and ABI (NCT02716532)
- Testing
- Peptamen AF
- Where
- Switzerland
- Volunteers
- 17 people
- Sponsor
- Société des Produits Nestlé (SPN)
Acute Ischemic Stroke
Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults
NTS-104 TRIS will be administered as a single intravenous dose to healthy subjects at doses of 0.8, 4, 8 and 16 mg/kg in 4 Cohorts.
- Trial name
- NCT05547438
- Testing
- NTS-104 TRIS
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- NeuroTrauma Sciences, LLC
Ischemic Stroke
A Phase Ib/II in Patients With Acute Ischemic Stroke
Stroke is the fifth leading cause of death in the United States and is the leading cause of long term disability. Distinct geographic disparities in stroke mortality, with highest rates in the southeast United States including…
- Trial name
- NCT02963376
- Testing
- 0.05 mL/kg DDFPe, 0.10 mL/kg DDFPe, 0.17 mL/kg DDFPe
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NuvOx LLC
Heart Failure, Congestive
PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
The study is being conducted to examine whether KW-3902IV will result in greater improvement in signs and symptoms of heart failure, with less treatment failure than standard therapy, when it is added to IV loop diuretics in…
- Trial name
- NCT00354458
- Testing
- rolofylline
- Volunteers
- 1,102 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Stroke
REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients
To assess the safety and tolerability of NTx™-265 when given to acute ischemic stroke patients. To assess the neurological outcome in acute ischemic stroke patients treated with NTx™-265, when compared with patients given a…
- Trial name
- REGENESIS (NCT00715364)
- Testing
- NTx™-265: rhCG, then rEPO
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Stem Cell Therapeutics Corp.
Stroke
Safety and Efficacy Study in Acute Ischaemic Stroke
A Phase II study to evaluate the safety and efficacy of five dose levels of study drug in acute ischaemic stroke
- Trial name
- VASST (NCT00144014)
- Testing
- V10153
- Where
- 28 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- Vernalis (R&D) Ltd
Heart Failure, Decompensated Heart Failure
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A randomized, double-blinded, placebo-controlled study of continuous 6-hour IV infusions of CXL-1427 in hospitalized patients with systolic heart failure.
- Conditions
- Heart Failure, Decompensated Heart Failure, Acute Heart Failure
- Trial name
- NCT02157506
- Testing
- CXL-1427
- Where
- 35 sites in United States, Germany and 3 more
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Acute Coronary Syndrome
Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes
The purpose of this study is to evaluate the safety and efficacy of various doses of YM150 (the experimental drug) in the prevention of ischemic vascular events in subjects with recent acute coronary syndromes.
- Trial name
- RUBY-1 (NCT00994292)
- Testing
- YM150
- Where
- 131 sites in Argentina, Australia and 19 more
- Volunteers
- 1,276 people
- Sponsor
- Astellas Pharma Europe B.V.
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Aortic Dissection, Distal Entry Tear
Guo&Amp;'s Distal Entry Tear Repair With WeFlow-EndoPatch System (Gallant Study)
A Multicenter, Randomized Controlled Study About the Safety and Efficacy of WeFlow-EndoPatch Aortic Endovascular Patch System manufactured by EndoNom Medtech (Hangzhou) Co., Ltd. for Chronic Aortic Dissection . (GALLANT Study)
- Trial name
- Gallant (NCT06945809)
- Testing
- WeFlow-EndoPatch Aortic Endovascular Patch System, Conventional Treatment group
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Hangzhou Endonom Medtech Co., Ltd.
Acute Myocardial Infarction
STEMI Cool Pilot Trial to Assess Cooling as an Adjunctive Therapy to PCI In Patients With Acute MI (Phase A)
A Multicenter, Prospective, Randomized-Controlled Trial to Assess Cooling as an Adjunctive Therapy to Percutaneous Intervention In Patients with Acute Myocardial Infarction.
- Trial name
- STEMI Cool (NCT03361995)
- Testing
- Cooling Procedure using the ZOLL Thermogard XP3 IVTM System, PCI
- Sponsor
- ZOLL Circulation, Inc., USA
Acute Ischemic Stroke, Transient Ischemic Attack (TIA)
A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention.
- Trial name
- AXIOMATIC-SSP (NCT03766581)
- Testing
- BMS-986177, Clopidogrel, Aspirin
- Where
- 424 sites in United States, Argentina and 27 more
- Volunteers
- 2,366 people
- Sponsor
- Bristol-Myers Squibb
Ventricular Septal Defect, Atrioventricular Septal Defect
A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects
This is a randomized, double-blind, placebo controlled, multicenter study to compare the efficacy and safety of L-citrulline versus placebo in patients undergoing surgery for congenital heart defects.
- Conditions
- Ventricular Septal Defect, Atrioventricular Septal Defect, Primum Atrial Septal Defect
- Trial name
- NCT05253209
- Testing
- L-citrulline, Plasmalyte A
- Where
- 10 sites in United States
- Volunteers
- 64 people
- Sponsor
- Asklepion Pharmaceuticals, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.